Zanidatamab for Colorectal Cancer

This trial aims to evaluate the effectiveness of zanidatamab, a special protein, when administered before surgery for colon and rectal cancer with high HER2 protein levels. Zanidatamab may inhibit the growth and spread of cancer cells. Individuals with HER2-positive colon or rectal cancer who plan to undergo surgery may be suitable candidates. The trial assesses zanidatamab alone or in combination with surgery to determine the optimal treatment approach for this cancer type. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get a clear answer.

Research has shown that zanidatamab has been tested for safety in patients with HER2-positive colorectal cancer. The studies found that zanidatamab, when used with chemotherapy, generally has a manageable safety profile. Most patients tolerated the treatment well.

Researchers are excited about zanidatamab for colorectal cancer because it targets the HER2 protein, which is overexpressed in some cancer cells, a mechanism not typically addressed by standard chemotherapy treatments like FOLFOX or FOLFIRI. Unlike conventional therapies that primarily focus on disrupting cell division, zanidatamab is a bispecific antibody that binds to two different sites on the HER2 protein, potentially leading to more effective cancer cell destruction. This targeted approach might offer improved efficacy and a different side-effect profile, which is particularly promising for patients who haven't responded well to other treatments.

Research has shown that zanidatamab may help treat several HER2-positive cancers, including colorectal cancer. In earlier studies, zanidatamab, often combined with chemotherapy, effectively treated HER2-positive metastatic colorectal cancer. Patients experienced significant tumor shrinkage and better disease control. In real-world use, zanidatamab allowed patients to live an average of 6.7 months without cancer progression and achieved a 65% success rate in shrinking or eliminating cancer in similar cases. In this trial, participants in Cohort 1 will receive zanidatamab followed by surgical resection, while those in Cohort 2 will receive zanidatamab alone, with optional surgical resection or observation. These findings suggest that zanidatamab could be effective for HER2-positive colorectal cancer.¹⁶⁷⁸⁹